Adjunctive Use of Mesenchymal Stem Cell Therapy in Children with Severe Acquired Brain Injury

Background

Severe acquired brain injury is a significant cause of long-term disability in children, often resulting from hypoxic-ischemic events or traumatic brain injury. Current therapeutic options are limited, primarily focusing on supportive care to prevent secondary brain injury. The exploration of MSC therapy as an adjunctive treatment aims to address the need for neurorestorative strategies in this vulnerable population, as noted in the literature.

Data Highlights

Key Findings

• Six pediatric patients received MSC therapy, with a median age of 65.5 months.
• Five patients had hypoxic brain injury, and one had a penetrating traumatic brain injury.
• All patients had a baseline PCPC of 5, indicating a coma or vegetative state.
• Median GCS improved from 4 at baseline to 11 after MSC therapy.
• PCPC scores decreased over time, indicating improved neurological function.
• No adverse events were reported during MSC administration or follow-up.

Clinical Implications

The findings suggest that MSC therapy may be a feasible adjunctive treatment for pediatric patients with severe acquired brain injury. However, due to the small sample size and lack of a control group, further controlled studies are necessary to validate these observations.

Conclusion

This case series indicates potential for MSC therapy in improving neurological outcomes in pediatric patients with severe acquired brain injury, but further research is essential to establish its efficacy.

Related Resources & Content

1. Brain Trauma Foundation, Guidelines for the Management of Pediatric Severe TBI, 3rd Edition
2. Comparative Analysis of Decompressive Craniectomy for Severe Traumatic Brain Injury in Pediatric Patients Versus Historical Data
3. Partly intraoperative cell salvage in pediatric craniocerebral trauma: effects on coagulation function, allogeneic blood requirements, and clinical outcomes
4. The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial
5. Frontiers in Oncology — Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years
6. Guidelines for the Management of Pediatric Severe TBI, 3rd Edition — Brain Trauma Foundation
7. Clinical and functional outcomes of stem cell therapy in the management of severe traumatic brain injury: a systematic review and meta-analysis | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Springer Nature Link